Is there a prognostic difference among stage I lung adenocarcinoma patients with different BRAF-mutation status?
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.BRAF mutations do not significantly impact prognosis in early-stage lung adenocarcinoma (LUAD). This study found no association between BRAF status and recurrence-free survival in stage I LUAD patients.
Area Of Science
- Oncology
- Genomics
- Cancer Research
Background
- Limited data exists on the prognostic role of V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations in early-stage lung adenocarcinoma (LUAD).
- Understanding BRAF mutation prevalence and its impact is crucial for treatment strategies in LUAD.
Purpose Of The Study
- To investigate the proportion and clinicopathological features of BRAF mutations in stage I LUAD patients.
- To determine the prognostic significance of BRAF mutations on recurrence-free survival (RFS) in stage I LUAD.
Main Methods
- Analysis of 431 stage I LUAD patients from cBioPortal and 1604 LUAD patients from Shanghai Pulmonary Hospital.
- Utilized Kaplan-Meier curves, log-rank tests, Cox proportional hazard models, propensity-score matching (PSM), and overlap weighting (OW) for survival analysis.
- Primary endpoint assessed was recurrence-free survival (RFS).
Main Results
- BRAF mutations were found in 5.6% of a Caucasian cohort; BRAF V600E mutations were detected in 1.4% (Caucasian) and 1.0% (Chinese) of patients.
- No significant association was found between BRAF mutations and worse RFS in stage I LUAD patients (HR=1.111, p=0.885), even after PSM and OW.
- BRAF V600E mutation status also lacked predictive significance for RFS.
Conclusions
- BRAF mutation status does not appear to be a significant predictor of prognosis in stage I lung adenocarcinoma.
- Further research and larger datasets are needed to validate these findings and their clinical implications.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...